Who are Terbinafine Tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lotrimin Ultra®, Tavaborole 5% Topical Solution, Jublia®, NAFT600 (pediatric), NAFT500 (pediatric), NAFT-500.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/terbinafine-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Terbinafine Tablets — Competitive Intelligence Brief

Terbinafine Tablets (Terbinafine Tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Allylamine antifungal. Area: Infectious Disease / Dermatology.

marketed Allylamine antifungal Squalene epoxidase Infectious Disease / Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Terbinafine Tablets (Terbinafine Tablets) — Oregon Health and Science University. Terbinafine inhibits fungal squalene epoxidase, disrupting ergosterol synthesis and causing fungal cell membrane collapse.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Terbinafine Tablets TARGET	Terbinafine Tablets	Oregon Health and Science University	marketed	Allylamine antifungal	Squalene epoxidase
Lotrimin Ultra®	Lotrimin Ultra®	Sun Pharmaceutical Industries, Inc.	marketed	Allylamine antifungal	Squalene epoxidase
Tavaborole 5% Topical Solution	Tavaborole 5% Topical Solution	Pfizer	marketed	Benzoxaborole antifungal	Squalene epoxidase
Jublia®	Jublia®	Dong-A ST Co., Ltd.	marketed	Azole antifungal	Squalene epoxidase (fungal)
NAFT600 (pediatric)	NAFT600 (pediatric)	Merz North America, Inc.	marketed	Topical antifungal (allylamine)	Squalene epoxidase (fungal)
NAFT500 (pediatric)	NAFT500 (pediatric)	Merz North America, Inc.	marketed	Allylamine antifungal	Squalene epoxidase
NAFT-500	NAFT-500	Merz North America, Inc.	phase 3	Benzylamine antifungal	Fungal sterol synthesis (squalene epoxidase inhibition)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Allylamine antifungal class)

Merz North America, Inc. · 3 drugs in this class
Sun Pharmaceutical Industries, Inc. · 2 drugs in this class
Bayer · 1 drug in this class
Oregon Health and Science University · 1 drug in this class
Pak Emirates Military Hospital · 1 drug in this class
Novartis · 1 drug in this class
Galderma R&D · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Terbinafine Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/terbinafine-tablets. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab